PubMed

Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.

Yangco BG, Von Bargen JC, Moorman AC, Holmberg SD.

Ann Intern Med. 2000 Feb 1;132(3):201-5.PMID: 10651600 [PubMed - indexed for MEDLINE]Related articlesFree article

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.

Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzáles-Lahoz J, d'Arminio Monforte A, Proenca R, Phillips AN, Lundgren JD, Reiss P.

Lancet. 1999 Apr 17;353(9161):1293-8.PMID: 10218526 [PubMed - indexed for MEDLINE]Related articles

A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.

Koletar SL, Heald AE, Finkelstein D, Hafner R, Currier JS, McCutchan JA, Vallee M, Torriani FJ, Powderly WG, Fass RJ, Murphy RL; ACTG 888 Study Team.

AIDS. 2001 Aug 17;15(12):1509-15.PMID: 11504983 [PubMed - indexed for MEDLINE]Related articles

Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators.

Moorman AC, Von Bargen JC, Palella FJ, Holmberg SD.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1;19(2):182-8.PMID: 9768629 [PubMed - indexed for MEDLINE]Related articles

Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.

Schneider MM, Borleffs JC, Stolk RP, Jaspers CA, Hoepelman AI.

Lancet. 1999 Jan 16;353(9148):201-3.PMID: 9923876 [PubMed - indexed for MEDLINE]Related articles

Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.

Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, Telenti A, Vernazza PL, Rickenbach M, Flepp M, Malinverni R.

N Engl J Med. 1999 Apr 29;340(17):1301-6.PMID: 10219064 [PubMed - indexed for MEDLINE]Related articlesFree article

Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.

Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, D'Arminio Monforte A, Schneider MM, Lundgren JD; Eight European Study Groups.

N Engl J Med. 2001 Jan 18;344(3):168-74.PMID: 11188837 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.

Lopez Bernaldo de Quiros JC, Miro JM, Peña JM, Podzamczer D, Alberdi JC, Martínez E, Cosin J, Claramonte X, Gonzalez J, Domingo P, Casado JL, Ribera E; Grupo de Estudio del SIDA 04/98.

N Engl J Med. 2001 Jan 18;344(3):159-67.PMID: 11172138 [PubMed - indexed for MEDLINE]Related articlesFree article

Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.

Abgrall S, Matheron S, Le Moing V, Dupont C, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV.

J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):151-8.PMID: 11242182 [PubMed - indexed for MEDLINE]Related articles

The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.

Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, Rathore M, Read JS, Huang S, Elgie C, Hudgens K, Hughes W.

Pediatrics. 2005 Apr;115(4):e488-94. Epub 2005 Mar 16.PMID: 15772172 [PubMed - indexed for MEDLINE]Related articlesFree article

Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.

D'Egidio GE, Kravcik S, Cooper CL, Cameron DW, Fergusson DA, Angel JB.

AIDS. 2007 Aug 20;21(13):1711-5.PMID: 17690568 [PubMed - indexed for MEDLINE]Related articles

Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J.

AIDS. 1999 Sep 10;13(13):1647-51.PMID: 10509565 [PubMed - indexed for MEDLINE]Related articles

Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.

Jones JL, Hanson DL, Dworkin MS, Alderton DL, Fleming PL, Kaplan JE, Ward J.

MMWR CDC Surveill Summ. 1999 Apr 16;48(2):1-22.PMID: 12412613 [PubMed - indexed for MEDLINE]Related articles

Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study.

Furrer H, Opravil M, Rossi M, Bernasconi E, Telenti A, Bucher H, Schiffer V, Boggian K, Rickenbach M, Flepp M, Egger M; Swiss HIV Cohort Study.

AIDS. 2001 Mar 9;15(4):501-7.PMID: 11242147 [PubMed - indexed for MEDLINE]Related articles

Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.

Mussini C, Pezzotti P, Antinori A, Borghi V, Monforte A, Govoni A, De Luca A, Ammassari A, Mongiardo N, Cerri MC, Bedini A, Beltrami C, Ursitti MA, Bini T, Cossarizza A, Esposito R; Changes in Opportunistic Prophylaxis (CIOP) Study Group.

Clin Infect Dis. 2003 Mar 1;36(5):645-51. Epub 2003 Feb 12.PMID: 12594647 [PubMed - indexed for MEDLINE]Related articles

Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.

Simonds RJ, Lindegren ML, Thomas P, Hanson D, Caldwell B, Scott G, Rogers M.

N Engl J Med. 1995 Mar 23;332(12):786-90.PMID: 7862183 [PubMed - indexed for MEDLINE]Related articlesFree article

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, De Luca A, Mongiardo N, Cerri MC, Chiodo F, Concia E, Bonazzi L, Moroni M, Ortona L, Esposito R, Cossarizza A, De Rienzo B.

J Infect Dis. 2000 May;181(5):1635-42. Epub 2000 May 15.PMID: 10823763 [PubMed - indexed for MEDLINE]Related articles

Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study.

Zellweger C, Opravil M, Bernasconi E, Cavassini M, Bucher HC, Schiffer V, Wagels T, Flepp M, Rickenbach M, Furrer H; Swiss HIV Cohort Study.

AIDS. 2004 Oct 21;18(15):2047-53.PMID: 15577626 [PubMed - indexed for MEDLINE]Related articles

1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.

[No authors listed]

MMWR Recomm Rep. 1995 Apr 28;44(RR-4):1-11.PMID: 7565543 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinic HIV-focused features and prevention of Pneumocystis carinii pneumonia.

Turner BJ, Markson L, Cocroft J, Cosler L, Hauck WW.

J Gen Intern Med. 1998 Jan;13(1):16-23.PMID: 9462490 [PubMed - indexed for MEDLINE]Related articlesFree article